Tr1X
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Tr1X sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Tr1X: 3 sponsored US clinical trials, 3 recruiting.
Tr1X sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Sclerosis (MS) Secondary Progressive, with 1 trials.
Upper-quartile sponsor footprint
Tr1X sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT07477639
Treatment of Moderate to Severe Refractory Crohn's Disease
NCT06721962
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
NCT06462365
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Therapeutic Areas
What is open in the Tr1X pipeline
3 recruiting of 3 indexed (100% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Multiple Sclerosis (MS) Secondary Progressive (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Tr1X: open-pipeline peers nationwide
Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Tr1X sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Tr1X page
3 registered trials is a research-attention snapshot, not an endorsement of Tr1X or any single study.
- 3 of Tr1X's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Sclerosis (MS) Secondary Progressive is the condition Tr1X studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Sclerosis (MS) Secondary Progressive trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Tr1X pipeline card: 3 registered trials from official public datasets.Report a data error.